Neptune Technologies & Bioresources
The 10-second takeaway
For the quarter ended Feb. 29 (Q4), Neptune Technologies & Bioresources missed estimates on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly and GAAP earnings per share expanded.
Margins grew across the board.
Neptune Technologies & Bioresources logged revenue of $5.4 million. The two analysts polled by S&P Capital IQ anticipated sales of $5.8 million on the same basis. GAAP reported sales were 29% higher than the prior-year quarter's $4.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.01. The two earnings estimates compiled by S&P Capital IQ predicted $0.00 per share. GAAP EPS were $0.01 for Q4 against -$0.05 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 53.8%, 6,760 basis points better than the prior-year quarter. Operating margin was -16.4%, 2,660 basis points better than the prior-year quarter. Net margin was 9.2%, 5,860 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $5.3 million. On the bottom line, the average EPS estimate is -$0.01.
Next year's average estimate for revenue is $27.0 million. The average EPS estimate is $0.03.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 23 members out of 162 rating the stock outperform, and 139 members rating it underperform. Among 87 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), three give Neptune Technologies & Bioresources a green thumbs-up, and 84 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Neptune Technologies & Bioresources is outperform, with an average price target of $9.09.
Over the decades, small-cap stocks like Neptune Technologies & Bioresources have produced market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: 2 Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add Neptune Technologies & Bioresources to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.